Short interest for Banco BBVA Argentina gives investors a sense of the degree to which investors are betting on the decline of Banco BBVA Argentina's stock. Short interest data is updated every two weeks.

Banco BBVA Argentina Stock (NYSE:BBAR), Short Interest Report

Banco BBVA Argentina

Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focused on foreign trade, agricultural business, and digital products.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AIRE

ALUR

ALZN

AUVI

AVXL

BBAR

BRSH

BSFC

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CEPU

CHGG

COIN

CUEN

CYTO

GGAL

GNLX

GTEC

GYRE

IOVA

KRON

LGMK

LOMA

MGOL

MIRA

MNOV

MOTS

NSTG

NTLA

PXMD

SGBX

Telecom Argentina Stet - France Telecom S.A.

THAR

TSVT

XPEV

YOSH

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales.

ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates of $258.41 million.

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Pre-Market Outlook

MSFT

U.S. stock futures traded slightly higher this morning on Monday, with the Dow Jones futures gaining around 15 points this morning.

Here are some big stocks recording gains in today’s pre-market trading session.

Microsoft, NIO And Other Big Stocks Moving Higher In Monday&#39;s Pre-Market Session

Bonds

Eurozone

BNPQY

UBS Group AG&#39;s (NYSE: UBS) takeover of Credit Suisse Group AG (NYSE: CBS) has done nothing to alleviate market concerns about the banking sector, and it continues to throw a shadow over the rights of credit institution sh

UBS Acquisition of Credit Suisse: Bye Bye AT1 Investors, Anxiety Builds Among Banks&#39; Subordinated Bondholders

Banco BBVA Argentina SA

<p>This article was originally published on <a href="https://www.leafly.com/news/health/weed-teen-mental-health-2024-analysis">Leafly.com</a> and appears here with permission.</p>
<p>If you read this January 10&nbsp;<a href="https://www.wsj.com/us-news/marijuana-depression-psychosis-869490d1" rel="noreferrer noopener" target="_blank"><em>Wall Street Journal</em>&nbsp;piece</a>, you might conclude that a wave of cannabis-induced psychosis among teenagers is sweeping the country. The story highlights research on the correlation between cannabis use and conditions like schizophrenia and bipolar disorder. It suggests access to higher-potency cannabis is leading to ever-increasing rates of psychosis in teens.&nbsp;</p>
<p>But the actual data paints a different picture. Population studies of&nbsp;<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800728#:~:text=Conclusions%20and%20Relevance%20In%20this,of%20psychosis%2Drelated%20health%20outcomes">over 63 million people</a>&nbsp;show that rates of psychosis do not go up amid legalization.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960330/" rel="noreferrer noopener" target="_blank">Teen use rates of marijuana are actually going down</a>. And our best science suggests that genetic factors&mdash;rather than cannabis use&mdash;are to blame for the correlation between cannabis and psychosis.&nbsp;</p>
<p>Can cannabis really induce life-long psychotic conditions&mdash;or is this yet another example of confusing correlation with causation, a common source of &ldquo;reefer madness?&rdquo;</p>
<h3 id="h-exploring-cannabis-psychosis-links">Exploring Cannabis-Psychosis Links</h3>
<p>The research on cannabis and psychosis is nuanced, but it definitely shows a strong correlation&mdash;as opposed to a&nbsp;<em>causation</em>&mdash;between the two. For instance, the data is clear that acute cannabis exposure&nbsp;<a href="https://www.nature.com/articles/1300496" rel="noreferrer noopener" target="_blank">can cause you to see vivid colors, or mis-hear sounds, or get anxious</a>. These experiences have been described as transitory &ldquo;psychosis-like&rdquo; episodes&mdash;particularly for&nbsp;<a href="https://academic.oup.com/ijnp/article/23/9/559/5834890?login=false" rel="noreferrer noopener" target="_blank">occasional users</a>.&nbsp;</p>
<h3 id="h-confusing-correlation-with-causation">Confusing Correlation With Causation</h3>
<p>With that in mind, it might not be surprising that when teens who use cannabis develop permanent psychosis-related conditions, their doctors and loved ones jump to the conclusion that cannabis caused the shift. There are numerous stories of teens who used cannabis and were subsequently diagnosed with these challenging, life-long conditions. Statistically, individuals who use cannabis&nbsp;<a href="https://www.thelancet.com/article/S2215-0366(19)30048-3/fulltext#:~:text=Daily" rel="noreferrer noopener" target="_blank">are more likely to have bipolar disorder or schizophrenia than the general population</a>.&nbsp;</p>
<p>But scientists have long struggled with the question of whether cannabis use actually causes these conditions&mdash;or if a third factor drives both. Based on cases where these conditions emerge&nbsp;<em>after</em>&nbsp;cannabis use, researchers&nbsp;<a href="https://www.sciencedirect.com/science/article/abs/pii/B9780128047910000082" rel="noreferrer noopener" target="_blank">estimate that cannabis-induced psychosis occurs in .0027% of consumers</a>. But even at this exceptionally rare rate, correlative studies can&rsquo;t prove whether cannabis is the cause of psychosis or not.&nbsp;</p>
<p>There are many ways to interpret the data that associate cannabis with psychosis. For example, individuals with psychosis conditions could be more likely to use cannabis in the first place, as a form of self-medication. If this were true, it would result in the same strong correlation.</p>
<h3 id="h-other-correlates-alcohol-tobacco">Other Correlates: Alcohol, Tobacco</h3>
<p>Cannabis certainly isn&rsquo;t the only factor linked with psychosis, even though it receives more publicity. Studies have found many things correlate with higher risk of psychosis,&nbsp;<em>including the use of any recreational substance</em>, like&nbsp;<a href="https://www.ncbi.nlm.nih.gov/books/NBK459134/" rel="noreferrer noopener" target="_blank">alcohol</a>&nbsp;and&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604123/" rel="noreferrer noopener" target="_blank">tobacco</a>. These substances are used&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035998/#:~:text=Individuals%20with%20schizophrenia%2Fpsychosis%20also,%25%2C%20p%3C0.001)." rel="noreferrer noopener" target="_blank">at similar rates</a>&nbsp;by schizophrenics as cannabis, and show similar statistical increases in psychosis risk. No one is debating, however, whether we should prohibit these substances.&nbsp;</p>
<h3 id="h-life-stressors">Life Stressors</h3>
<p><a href="https://www.healthline.com/health/stress-induced-psychosis#treatment" rel="noreferrer noopener" target="_blank">Stress</a>&nbsp;also frequently correlates to psychosis. The stress associated with an event like a teenager leaving home to begin college can trigger an initial psychotic episode.</p>
<p>One&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775150/" rel="noreferrer noopener" target="_blank">review study</a>&nbsp;found that the strongest factors correlated with developing lasting psychosis include a) living in an urban area and b) being an ethnic minority. Since cannabis is often used to combat stress, it&rsquo;s possible that people who are stressed out enough to develop psychosis are more likely to seek out cannabis.</p>
<h3 id="h-spice-k-2-and-designer-drugs-nbsp">Spice, K-2, And Designer Drugs&nbsp;</h3>
<p>And lastly, studies that associate cannabis with psychosis don&rsquo;t specify which specific cannabinoids are at play. For example, businesses like head shops and truck stops sell unlicensed, unregulated&mdash;and often illegal&mdash;synthetic cannabinoids (<a href="https://www.leafly.com/news/cannabis-101/what-is-thc-o">THC-O</a>,&nbsp;<a href="https://www.leafly.com/news/science-tech/thcp-cbdp-study-reveals-identification-two-new-cannabinoids">THC-P</a>,&nbsp;<a href="https://www.leafly.com/news/strains-products/what-is-hhc">HHC</a>, etc.) that can be hundreds of times more powerful than THC alone.&nbsp;</p>
<p>The use of dangerous synthetics like&nbsp;<a href="https://www.leafly.com/news/cannabis-101/what-is-synthetic-marijuana-and-why-is-it-dangerous">Spice</a>&nbsp;prevails in states that lack access to legal botanical THC. Athletic and military THC testing regimes also induce players and servicemembers to seek out novel, dangerous synthetics that won&rsquo;t show up in a drug test.</p>
<p>Data suggests that using synthetic cannabinoids&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450675/" rel="noreferrer noopener" target="_blank">can induce more symptoms of psychosis</a>&nbsp;than natural cannabis.</p>
<h2 id="h-legalization-isn-t-increasing-teen-use">Legalization Isn&rsquo;t Increasing Teen Use</h2>
<p>Some research also suggests that cannabis use among teenagers in particular&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/33617756/" rel="noreferrer noopener" target="_blank">has a strong correlation with a subsequent diagnosis of a psychosis-related condition</a>. This could mean that teens are particularly vulnerable to cannabis&rsquo; effects. But it could also point towards the fact that conditions like&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266753/" rel="noreferrer noopener" target="_blank">bipolar disorder</a>&nbsp;and&nbsp;<a href="https://www.nimh.nih.gov/health/statistics/schizophrenia" rel="noreferrer noopener" target="_blank">schizophrenia</a>&nbsp;are most commonly identified and diagnosed while patients are in their twenties, while&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593777/#:~:text=For%20cannabis%20initiation%2C%20reported%20ages,SD%3D3.2)%20for%20women." rel="noreferrer noopener" target="_blank">cannabis use usually begins during teenage years</a>. It is possible that individuals with these conditions would be more likely to self-medicate with cannabis; since this typically occurs before their diagnosis, doctors and scientists would assume that cannabis&nbsp;<em>caused</em>&nbsp;the psychosis-like condition.</p>
<p>While many prohibitionists would use any potential for teen psychosis as a reason to limit cannabis legalization, it&rsquo;s important to note that&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960330/" rel="noreferrer noopener" target="_blank">rates of teen cannabis use are going down,</a>&nbsp;not up, as states legalize cannabis. Street dealers do not check ID, but legitimate dispensaries do. This means that legalization tends to limit teen access, rather than increasing it.&nbsp;</p>
<h2 id="h-psychosis-rates-do-not-increase-with-cannabis-legalization-nbsp">Psychosis Rates *Do Not* Increase With Cannabis Legalization&nbsp;</h2>
<p>Fortunately, scientists dig deeper than simple correlative studies. For instance, they look at the rates of psychosis in places where cannabis is more available. If cannabis&rsquo; prevalence causes psychosis, it would follow that as cannabis access increases, we would see rising rates of psychosis.&nbsp;</p>
<p>While legalization&nbsp;<em>does</em>&nbsp;increase rates of other conditions that are directly triggered by cannabis use, such as&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624147/#:~:text=Previous%20studies%20have%20shown%20an,Colorado%20EDs%20after%20cannabis%20legalization." rel="noreferrer noopener" target="_blank">cannabinoid hyperemesis syndrome</a>, the studies that examine psychosis rates have had very mixed results.&nbsp;</p>
<p>The&nbsp;<em>WSJ</em>&nbsp;article mentioned earlier in this article cites a&nbsp;<a href="https://www.thelancet.com/article/S2215-0366(19)30048-3/fulltext" rel="noreferrer noopener" target="_blank">small Danish study</a>&nbsp;that examined data collected from 6,788 people in 11 locations throughout Europe and Brazil. None had access to tested, legal cannabis.</p>
<p>While it did find a link between access to high-potency cannabis and psychosis, a&nbsp;<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800728#:~:text=Conclusions%20and%20Relevance%20In%20this,of%20psychosis%2Drelated%20health%20outcomes" rel="noreferrer noopener" target="_blank">much larger US study</a>&nbsp;involving over 63 million people found that access to medical or recreational cannabis had no impact on psychosis rates at all. If we were seeing a dramatic wave of teen psychosis in the US, as suggested in the recent&nbsp;<em>WSJ</em>&nbsp;piece, that shift should be reflected in this large-scale population study.&nbsp;</p>
<h2 id="h-genetics-may-drive-cannabis-use-as-well-as-mental-health-outcomes-nbsp">Genetics May Drive Cannabis Use As Well As mental Health Outcomes&nbsp;</h2>
<p>Psychosis rates haven&rsquo;t skyrocketed with the recent increase in legal cannabis access, so why do we see any correlation between the two?&nbsp;</p>
<p>Beyond the possibilities suggested above, genetics may play a key role. Scientists have found data that points to&nbsp;<a href="https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2021.21111126" rel="noreferrer noopener" target="_blank">underlying genes that predispose someone to both psychosis and cannabis-use disorder</a>. (Doctors&nbsp;<a href="https://www.ncbi.nlm.nih.gov/books/NBK538131/" rel="noreferrer noopener" target="_blank">diagnose cannabis-use disorder</a>&nbsp;when someone experiences negative effects from cannabis use, wants to stop using it, but cannot bring themselves to quit despite repeated efforts.)</p>
<p>Research reviews have found that an individual who has genetics correlated with cannabis-use disorder may be more likely to develop schizophrenia,&nbsp;<em>whether or not they actually ever used cannabis.&nbsp;</em>This suggests that genetics, rather than cannabis, is to blame.&nbsp;</p>
<p>One the best-designed studies just came out. In January, researchers published a&nbsp;<a href="https://psycnet.apa.org/record/2024-40025-005">rare study of more than 4,000 identical twins</a>&nbsp;over time. One twin used weed while the other didn&rsquo;t, and researchers tracked them for 27 years. Weed use did not predict mental health outcomes.</p>
<p>&ldquo;Cannabis consumption did not predict within-pair differences in psychoticism,&rdquo; the researchers concluded.</p>
<p>There&rsquo;s a big takeaway here: If you have a family history of mental illness, and are increasing your cannabis use, you might want to re-evaluate your habits.</p>
<p>The data also supports maintaining 21 as the legal appropriate age for cannabis consumption; that&rsquo;s typically towards the back end of when congenital mental illness may crop up in an individual.&nbsp;</p>
<p>While more research may shift our understanding of these issues, the current data does not suggest that cannabis use is a strong causal factor for chronic mental illness. Still, given cannabis&rsquo; ability to cause visual effects or strange thoughts, THC may be best avoided by at-risk patients. At the same time, doctors are actively evaluating whether the cannabinoid CBD can treat mental illnesses.&nbsp;</p>
<p>As always, consult with a cannabis-specializing doctor before beginning medical use of cannabis to treat your symptoms. &nbsp;</p>
<p>This article is from an external unpaid contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</p>


Cannabis

General

Fact Check: Is Marijuana Legalization Hurting Teen Mental Health?

<p>Piper Sandler  analyst Ryan Todd   maintains PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) with a Neutral and lowers the price target from $61 to $54.</p>


Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on PBF Energy, Lowers Price Target to $54

<p><em>This article was originally published on <a href="https://cannabis.net/blog/news/buy-sell-puff-puff-pass-wall-street-drops-drug-testing-for-cannabis-what-it-could-mean-for-your">Cannabis.net</a> on Friday, Feb 9, 2024, and appears here with permission.</em></p>
<p>Earlier this year, we found out that major Wall Street banks were forgoing drug testing for applicants, including marijuana, in a significant shift from customary standards. This trend mirrors wider shifts in legal and cultural views, as well as the rising acceptance of cannabis use in professional groups.</p>
<p>The following lists the modifications that major financial institutions are implementing,&nbsp;<a href="https://www.businessinsider.com/wall-street-big-banks-no-longer-testing-marijuana#:~:text=BI%20asked%20the%20largest%20banks,hiring%20and%20employee%20screening%20process.">as reported by Business Insider:</a></p>
<p>Bank of America Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>): No longer conducts drug testing for new hires or current employees.</p>
<p>Citigroup Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>): Employment does not require drug testing, with a focus on evaluating involvement with the cannabis industry.</p>
<p>The Goldman Sachs Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>): Has recently amended its policy to exclude marijuana from drug testing for new hires.</p>
<p>JPMorgan Chase &amp; Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>): Policy on drug testing was not provided, but the company has previously tested employees of suppliers.</p>
<p>Morgan Stanley (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ms#NYSE">MS</a>): Does not require drug testing for existing employees or new hires.</p>
<p>UBS Group AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ubs#NYSE">UBS</a>): UBS did not comment on its post-acquisition policies, while Credit Suisse declined to discuss past practices.</p>
<p>Wells Fargo &amp; Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wfc#NYSE">WFC</a>): Maintains a drug-free workplace but does not conduct pre-employment marijuana screening.</p>
<p>This trend among Wall Street institutions reflects a broader reevaluation of cannabis nationwide, influenced by its legal status in multiple U.S. states and evolving public sentiment.</p>
<p>The shift is driven in part by practical considerations, such as the difficulty of enforcing stringent drug-free policies in areas where cannabis is legal and the necessity of attracting top talent in a competitive job market.</p>
<p><strong>The Decline in Workplace Drug Testing</strong></p>
<p>Recent studies and reports have shed light on a significant&nbsp;<a href="https://cannabis.net/blog/news/record-numbers-of-americans-are-failing-workplace-drug-tests-due-to-cannabis-so-what-is-the-ans">reduction in the requirement for drug testing among companies</a>. This downward trend is influenced by various factors, including changes in legalization, a reevaluation of the effectiveness of such policies, and a greater emphasis on respecting the privacy rights and personal freedoms of employees.&nbsp; Wall Street&nbsp;<a href="https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022">trading options like cannabis and psychedelic stock ETFs</a>&nbsp;are now commonplace for investors to look into and invest in as well.</p>
<p>Several U.S. states have passed legislation that forbids businesses from treating current workers or job candidates differently because they use cannabis outside of work due to changing legal environments. The emerging<a href="https://cannabis.net/blog/opinion/weed-and-work-all-your-employees-are-using-cannabis-and-that-is-a-good-thing">&nbsp;understanding that recreational cannabis use</a>&nbsp;during one&#39;s free time does not always affect one&#39;s ability to do their job or the safety of the workplace is reflected in these legislative amendments.</p>
<p>This change in strategy reflects a significant shift in how companies handle cannabis use among their employees. It signals the beginning of a new age in employment practices that will prioritize workplace efficiency and safety while also placing a greater focus on respecting individuals&#39; rights and privacy.</p>
<p>Overall, this trend signals a departure from the previous stringent stance on drug testing, toward a more nuanced understanding of employee behavior and rights. It underscores the importance of balancing regulatory requirements with considerations for individual autonomy and the changing societal attitudes towards cannabis use.</p>
<p><strong>Navigating Legal and Cultural Shifts</strong></p>
<p>The&nbsp;<a href="https://cannabis.net/blog/opinion/marijuana-in-the-workplace-how-to-prepare-as-a-business-owner">landscape of workplace drug testing</a>, particularly regarding cannabis, is undergoing a profound transformation in response to shifting legal and cultural dynamics. Across the United States, the trajectory of cannabis legalization has shifted markedly, with many states moving towards decriminalization or outright legalization for both medical and recreational use. This legal evolution prompts a reassessment of corporate policies, as employers navigate the delicate balance between compliance and adapting to changing societal expectations.</p>
<p>Simultaneously, cultural attitudes towards cannabis have undergone a significant shift, moving away from stigmatization towards a more nuanced understanding. Cannabis is increasingly embraced for its therapeutic benefits and recreational use, altering perceptions around its role in both personal and professional spheres. This cultural shift underscores the need for employers, particularly in industries such as finance, to recalibrate their approach to drug testing in alignment with evolving societal norms.</p>
<p>Major financial institutions on Wall Street are responding to these legal and cultural shifts by reevaluating their drug testing policies, particularly regarding marijuana screening for job applicants. By eschewing traditional practices in favor of a more progressive stance, these institutions are not only adapting to the changing legal landscape but also signaling a commitment to fostering inclusive and forward-thinking workplace environments. However, navigating the complex patchwork of state regulations and ensuring compliance while respecting employee rights remain ongoing challenges for employers in this evolving landscape.</p>
<p><strong>Redefining Employment Standards on Wall Street</strong></p>
<p>The transformation in drug testing practices among major financial institutions signifies a redefinition of employment standards on Wall Street and beyond. Departing from conventional norms, these institutions are opting out of marijuana and substance testing for job applicants, marking a significant departure from traditional hiring protocols. This shift underscores a broader recognition of the evolving landscape surrounding cannabis use in professional environments and reflects a commitment to aligning recruitment practices with contemporary attitudes and legal frameworks.</p>
<p>By forgoing drug testing, Wall Street banks are not only reshaping their hiring processes but also signaling a departure from outdated practices that may no longer align with modern values and regulations. This redefinition of employment standards reflects a strategic adaptation to the changing expectations of both employees and the broader society, positioning these institutions as forward-thinking and responsive to societal shifts.</p>
<p>Moreover, this change in employment standards affects more than just Wall Street; it acts as a gauge for more general changes in employment practices in a variety of businesses. As the biggest financial institutions reform their drug-testing practices, they create a precedent that encourages other businesses to reevaluate their own rules, resulting in a more inclusive and progressive workplace environment. This revised standard emphasizes how crucial it is to be flexible and responsive in order to be relevant and competitive in the quickly changing corporate world of today.</p>
<p><strong>Bottom Line</strong></p>
<p>The shift away from marijuana and substance testing among major Wall Street banks marks a significant departure from traditional hiring practices, reflecting broader changes in legal, cultural, and societal attitudes toward cannabis. This trend highlights a strategic response to evolving expectations, balancing regulatory compliance with the need to attract top talent in a&nbsp;<a href="https://jobs.cannabis.net/">competitive job market</a>. As financial institutions redefine their employment standards, they set a precedent for progressive workplace practices, emphasizing the importance of adaptability and responsiveness in today&#39;s dynamic business environment.</p>
<p>This article is from an external unpaid contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</p>


Buy! Sell! Puff! Pass! What Wall Street Dropping Drug Testing For Cannabis Could Mean For Your 401k

<p>Benchmark  analyst Reuben Garner   reiterates Janus Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) with a Buy and maintains $21 price target.</p>


Reiteration

Benchmark Reiterates Buy on Janus Intl Gr, Maintains $21 Price Target

WIIM

VRCA

Verrica Pharmaceuticals shares are trading higher are trading higher possibly amid strength in high-short interest stocks after retail trader 'Roaring Kitty' returned to social media. Also, Needham and HC Wainwright raised their respective price targets on the stock.

Guidance

GRFS

Grifols On Track To Meet FY Guidance And Reduce Debt

<p>Piper Sandler  analyst Ryan Todd   maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Overweight and lowers the price target from $187 to $170.</p>


Piper Sandler Maintains Overweight on Phillips 66, Lowers Price Target to $170

<p>Piper Sandler  analyst Ryan Todd   maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Neutral and lowers the price target from $204 to $190.</p>


Piper Sandler Maintains Neutral on Marathon Petroleum, Lowers Price Target to $190

<p>Piper Sandler  analyst Ryan Todd   maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Overweight and lowers the price target from $198 to $187.</p>


Piper Sandler Maintains Overweight on Valero Energy, Lowers Price Target to $187

<p>"Facebook according to an internal memo is recommending Zoom-owned Workvivo as a migration-ready alternative. Workvivo, another enterprise communication platform, was <a href="https://techcrunch.com/2023/04/14/zoom-acquires-ireland-based-employee-communications-platform-workvivo/">acquired by Zoom in 2023</a>. We have the full memo below."&nbsp;</p>
<p><a href="https://techcrunch.com/2024/05/14/sources-meta-is-shutting-down-workplace-its-enterprise-communications-business/">https://techcrunch.com/2024/05/14/sources-meta-is-shutting-down-workplace-its-enterprise-communications-business/</a></p>


Sources: Meta is shutting down Workplace, its enterprise communications business

<p>Piper Sandler  analyst Ryan Todd   maintains Par Pacific Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PARR#NYSE">PARR</a>) with a Overweight and lowers the price target from $47 to $43.</p>


PARR

Piper Sandler Maintains Overweight on Par Pacific Hldgs, Lowers Price Target to $43

<p>TD Cowen  analyst Andrew Charles   reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and maintains $73 price target.</p>


JACK

TD Cowen Reiterates Hold on Jack In The Box, Maintains $73 Price Target

SCHW

Schwab shares are trading higher after the company reported total net new assets of $10 billion in April.

RXRX

Recursion Pharmaceuticals shares are trading higher possibly amid strength in high-short interest stocks after retail trader 'Roaring Kitty' returned to social media. The stock may also be moving amid continued strength after the company announced on Monday the completion of BioHive-2.

<p>Piper Sandler  analyst Ryan Todd   maintains Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) with a Neutral and lowers the price target from $31 to $30.</p>


Piper Sandler Maintains Neutral on Delek US Hldgs, Lowers Price Target to $30

Marathon Petroleum shares are trading lower following a CEO transition.

Macro Economic Events

Economics

Oil is trading lower following hotter-than-expected US inflation data.

<p>RBC Capital  analyst Leonid Timashev   maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Outperform and raises the price target from $85 to $86.</p>


LEGN

RBC Capital Maintains Outperform on Legend Biotech, Raises Price Target to $86

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Carnival</strong>.</p>
<p>Looking at options history for Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 0% of the investors opened trades with bullish expectations and 100% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $697,166 and 4, calls, for a total amount of $140,130.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $14.0 to $20.0 for Carnival over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Carnival options trades today is 17334.75 with a total volume of 16,837.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Carnival's big money trades within a strike price range of $14.0 to $20.0 over the last 30 days.</p>
<h3>Carnival 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715700710_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.49</td>
<td>$0.48</td>
<td>$0.49</td>
<td>$14.00</td>
<td>$524.0K</td>
<td>14.9K</td>
<td>4.1K</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.48</td>
<td>$0.46</td>
<td>$0.48</td>
<td>$14.00</td>
<td>$57.7K</td>
<td>14.9K</td>
<td>4.0K</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.48</td>
<td>$0.46</td>
<td>$0.48</td>
<td>$14.00</td>
<td>$48.0K</td>
<td>14.9K</td>
<td>2.8K</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$0.89</td>
<td>$0.86</td>
<td>$0.86</td>
<td>$15.00</td>
<td>$39.1K</td>
<td>7.9K</td>
<td>537</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.48</td>
<td>$0.46</td>
<td>$0.48</td>
<td>$14.00</td>
<td>$38.1K</td>
<td>14.9K</td>
<td>1.8K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Carnival</h3>
<p>Carnival is the largest global cruise company, with 92 ships in service at the end of fiscal 2023. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&amp;O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe; and P&amp;O Cruises in Australia. Carnival also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 13 million guests in 2019, prior to covid-19, a level it reached again in 2023.</p>
<p>Having examined the options trading patterns of Carnival, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Carnival</h3>
<ul>
<li>Currently trading with a volume of 8,781,242, the CCL's price is up by 0.27%, now at $14.6. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 41 days.</li>
</ul>
<h3>Professional Analyst Ratings for Carnival</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $21.0.</p>
<ul>
<li>An analyst from UBS has decided to maintain their Buy rating on Carnival, which currently sits at a price target of $21. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Carnival with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Check Out What Whales Are Doing With CCL

<p>Deep-pocketed investors have adopted a bullish approach towards Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Goldman Sachs Gr. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 46% leaning bullish and 40% bearish. Among these notable options, 4 are puts, totaling $175,059, and 11 are calls, amounting to $499,021.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $640.0 for Goldman Sachs Gr over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Goldman Sachs Gr's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Goldman Sachs Gr's whale activity within a strike price range from $400.0 to $640.0 in the last 30 days. </p>
<h3>Goldman Sachs Gr Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715700705_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$41.95</td>
<td>$40.25</td>
<td>$40.65</td>
<td>$425.00</td>
<td>$81.3K</td>
<td style="text-align: right;">561</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/24/24</td>
<td>$20.55</td>
<td>$19.6</td>
<td>$20.55</td>
<td>$480.00</td>
<td>$71.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$23.0</td>
<td>$20.55</td>
<td>$23.0</td>
<td>$640.00</td>
<td>$69.0K</td>
<td style="text-align: right;">100</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/24/24</td>
<td>$6.6</td>
<td>$6.45</td>
<td>$6.46</td>
<td>$460.00</td>
<td>$64.8K</td>
<td style="text-align: right;">311</td>
<td style="text-align: right;">247</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$23.0</td>
<td>$20.55</td>
<td>$23.0</td>
<td>$640.00</td>
<td>$48.3K</td>
<td style="text-align: right;">100</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Goldman Sachs Gr</h3>
<p>Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.</p>
<p>Following our analysis of the options activities associated with Goldman Sachs Gr, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Goldman Sachs Gr</h3>
<ul>
<li>Trading volume stands at 710,098, with GS's price up by 1.65%, positioned at $461.05.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 64 days.</li>
</ul>
<h3>What Analysts Are Saying About Goldman Sachs Gr</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $449.0.</p>
<ul>
<li>An analyst from Oppenheimer persists with their Outperform rating on Goldman Sachs Gr, maintaining a target price of $517. </li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Goldman Sachs Gr with a target price of $433. </li>
<li>An analyst from Argus Research has elevated its stance to Buy, setting a new price target at $465. </li>
<li>An analyst from Citigroup persists with their Neutral rating on Goldman Sachs Gr, maintaining a target price of $425. </li>
<li>Maintaining their stance, an analyst from RBC Capital continues to hold a Sector Perform rating for Goldman Sachs Gr, targeting a price of $405. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Goldman Sachs Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Goldman Sachs Gr's Options Frenzy: What You Need to Know

UP Fintech Holding in financials losers, Grupo Financiero among gainers

Banco BBVA Argentina: Caution Warranted Ahead Of More 'Shock Therapy'

Notable earnings after Tuesday's close

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Banco BBVA Argentina</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/bbar-stock-quote/"><strong>BBAR</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Banco BBVA Argentina reported earnings per share of 59 cents.</li><li>The company reported revenue of $1.21 billion.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/bbar-stock-earnings-banco-bbva-argentina-for-q4-of-2023/">BBAR Stock Earnings: Banco BBVA Argentina Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BBAR Stock Earnings: Banco BBVA Argentina Reported Results for Q4 2023

Banco BBVA Argentina reports Q4 results

Banco BBVA Argentina S.A. SPON ADS EACH REP 3 ORD SHS (BBAR) Q4 2023 Earnings Call Transcript

Banco BBVA Argentina S.A. SPON ADS EACH REP 3 ORD SHS 2023 Q4 - Results - Earnings Call Presentation

Blue Owl Capital, B. Riley Financial among financial movers

Banco BBVA Argentina: The Trend Is Your Friend

Argentine banks rise, bitcoin miners fall in earnings-packed week: financials roundup

AEVA

APEI

AQST

BASE

BKCC

BNGO

BTOG

CDRE

CERS

CHPT

CLSK

CRCT

CRWD

CXDO

GLRE

HIPO

KYCH

MARA

MRNS

NEWT

NVEI

NYCB

OFIX

PSTV

RELI

RIGL

RILY

RIOT

ROST

SMLR

SOFI

SUPV

TCON

TIGR

UMAC

Dividends

Press Releases

Banco BBVA Argentina S.A. announces dividend payment - Installment 3 of 6

BBVA Argentina announces Second Quarter 2023 Financial Results Schedule

Earnings

Banco BBVA Argentina S.A. announces Second Quarter 2023 results

Banco BBVA Argentina S.A. announces dividend payment - Installment 4 of 6

Banco BBVA Argentina S.A. announces dividend payment - Installment 5 of 6

Banco BBVA Argentina S.A. announces Third Quarter 2023 results

BBVA Argentina announces Fourth Quarter and Fiscal Year 2023 Financial Results Schedule

Banco BBVA Argentina S.A. announces Fourth Quarter and Fiscal Year 2023 results

Banco BBVA Argentina has filed its Annual Report on Form 20-F for the fiscal year 2023

BBVA Argentina announces First Quarter 2024 Financial Results Schedule

Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones

Credicorp

Banco De Chile

Banco Macro S.A. ADR (representing Ten Class B Common Shares)

Banco Macro

Banco Santander Chile

BanColombia

Comerica

Grupo Financiero Galicia S.A. - American Depositary Shares, Class B Shares underlying

Grupo Financiero Galicia

Intercorp Financial Services Inc. Common Shares

Intercorp Financial Servs

Inter & Co

KeyCorp

Grupo Supervielle S.A. American Depositary Shares each Representing five Class B shares

Grupo Supervielle

Woori Financial Group Inc. American Depositary Shares (each representing three (3) shares of Common Stock)

Woori Financial Group

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Banco BBVA Argentina Stock (NYSE:BBAR), Short Interest Report

People Also Watch